Devil's Deal?

While personalized medicine may be able to tailor treatments to patients' specific maladies, Eleonore Pauwels and Jim Dratwa from the Woodrow Wilson International Center wonder whether it is a sort of Faustian bargain. Many of the people who contribute their DNA toward the development of personalized medicine may not be able to reap its benefits, they write at the Scientific American Guest Blog.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.